Publications related to Cancer of unknown primary origin

The role of LRRK2 in lung adenocarcinoma

Lung cancer is the leading cause of cancer-related deaths worldwide and the most common lung cancer subtype is lung adenocarcinoma (LUAD). Frequently mutated genes involve activating mutations in KRAS and loss of function mutations in TP53. LUADs primarily ...

EPFL2024

Tumor dormancy: EMT beyond invasion and metastasis

Cathrin Brisken, Hazel Margaret Quinn, Patrik Aouad

More than two-thirds of cancer-related deaths are attributable to metastases. In some tumor types metastasis can occur up to 20 years after diagnosis and successful treatment of the primary tumor, a phenomenon termed late recurrence. Metastases arise from ...

WILEY2023

Medical and Personal Characteristics Can Predict the Risk of Lung Metastasis

Michele De Palma, Nahal Mansouri

Aims: Understanding the correlations between underlying medical and personal characteristics of a patient with cancer and the risk of lung metastasis may improve clinical management and outcomes. We used machine learning methodologies to predict the risk o ...

2023

Investigating the effect of inflammation on the progression of B-cell lymphoma dissemination in the sentinel lymph node

Daniel Molina Romero

Lymphomas are a group of heterogeneous blood cancers that arise from lymphocytes. The two primary clinical classifications of lymphomas are Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL). In particular, B-cell lymphoma refers to the malignancies ...

EPFL2023

Pan-cancer atlas of somatic core and linker histone mutations

Sebastian Martin Waszak

Recent genomic data points to a growing role for somatic mutations altering core histone and linker histone-encoding genes in cancer. However, the prevalence and the clinical and biological implications of histone gene mutations in malignant tumors remain ...

2023

Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma

Cathrin Brisken, Laura Battista, Georgios Sflomos

Simple Summary Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer and is often detected at an advanced stage. Up to 30% of ILC cases relapse and present a challenge for treatment. Unfortunately, there are few mod ...

MDPI2023

Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers

Wouter Richard Karthaus

In lung and prostate adenocarcinomas, neuroendocrine (NE) transformation to an aggressive derivative resembling small cell lung cancer (SCLC) is associated with poor prognosis. We previously described dependency of SCLC on the nuclear transporter exportin ...

2023

Metabolic dependencies of metastasis-initiating cells in female breast cancer

Albert Santamaria Martinez, Pierre Vincent Dessen, Jörg Hülsken, Laurent Nam Ky Beziaud, Angela Madurga Alonso, Candice Megan T Young

Understanding the mechanisms that enable cancer cells to metastasize is essential in preventing cancer progression. Here we examine the metabolic adaptations of metastasis-initiating cells (MICs) in female breast cancer and how those shape their metastatic ...

Nature Portfolio2023

The role of eosinophils in breast cancer

Luisa Spisak

Eosinophils are granulocytes and belong to the innate arm of immunity. Eosinophils can be in different basal or activation states and depending on which type of activation is applied, they exert different effector functions. These multi-functional cells ha ...

EPFL2022

Immunosuppressive roles of Activin-A in melanoma and characterization of its precursor cleavage

Katarina Pinjusic

Activin-A, a transforming growth factor ê µ family member, is a pleiotropic cytokine with diverse functions in development, fertility, adult tissue homeostasis, and aging. Accordingly, deregulation of Activin-A signaling has been associated with many patho ...

EPFL2022

Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence

Cathrin Brisken, Giovanna Ambrosini, Georgios Sflomos, Yueyun Zhang, Hazel Margaret Quinn, Fabio De Martino, Patrik Aouad, Céline Marie Victoria Stibolt, Kelly Spry Maggs

More than 70% of human breast cancers (BCs) are estrogen receptor α-positive (ER+). A clinical challenge of ER+ BC is that they can recur decades after initial treatments. Mechanisms governing latent disease remain elusive due to lack of adequate in vivo m ...

Nature Research2022

Intraductal xenografts model estrogen receptor-positive (ER+) breast cancer dormancy and reveal a critical role for epithelial-mesenchymal transition (EMT) in its establishment

Patrik Aouad

Compared to estrogen receptor-negative (ER-) breast cancer (BC), ER+ BC often manifests with a latent disease that recurs decades after initial diagnosis. The mechanisms governing dormancy and distant recurrence of ER+ tumors remain elusive due to the lack ...

EPFL2021

Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1

Cathrin Brisken, Giovanna Ambrosini, Ayyakkannu Ayyanan, Georgios Sflomos, Laura Battista, Philipp Bucher, Valentina Scabia, Maryse Fiche, Fabio De Martino, Patrik Aouad

Invasive lobular carcinoma (ILC) is the most frequent special histological subtype of breast cancer, typically characterized by loss of E‐cadherin. It has clinical features distinct from other estrogen receptor‐positive (ER+) breast cancers but the molecul ...

2021

Tracing of Human Tumor Cell Lineages by Mitochondrial Mutations

Stephan Morgenthaler, Paul Refinetti, Per Olaf Ekstrom

Background ...

FRONTIERS MEDIA SA2020

Metabolic plasticity and glucose transporter redundancy dictate lung adenocarcinoma growth

Caroline Anne-Lyse Contat

Lung cancers represent the leading cause of cancer-related deaths worldwide. These pulmonary cancers count several histological subgroups, whose non-small cell lung cancers, subject of our study. We were precisely interested in the most common subtype of n ...

EPFL2020

FMRP and cancer treatment

Douglas Hanahan, Qiqun Zeng

The present invention provides compositions and methods for down-modulating the expression and/or the immuno-suppressive activity of i) the FMRP protein, ii) an mRNA encoding the FMRP protein, and/or iii) the FMR1 gene for the treatment and/or prevention o ...

2020

Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity

Cathrin Brisken, Georgios Sflomos, Laura Battista

Functional studies giving insight into the biology of circulating tumor cells (CTCs) remain scarce due to the low frequency ofCTCs and lack of appropriate models. Here, we describe the characterization of a novelCTC-derived breast cancer cell line, designa ...

2020

Somatic Mitochondrial DNA Point Mutations Used as Biomarkers to Demonstrate Genomic Heterogeneity in Primary Prostate Cancer

Paul Refinetti, Per Olaf Ekstrom

Primary prostate tumor heterogeneity is poorly understood, leaving research efforts with challenges regarding the initiation and advancement of the disease. The growth of tumor cells is accompanied by mutations in nuclear and in mitochondrial genomes. Thus ...

HINDAWI LTD2020

STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway

Friedrich Beermann

Metastatic melanoma is hallmarked by its ability of phenotype switching to more slowly proliferating, but highly invasive cells. Here, we tested the impact of signal transducer and activator of transcription 3 (STAT3) on melanoma progression in association ...

SPRINGERNATURE2021

NovelT2Mapping for Evaluating Cervical Cancer Features by Providing QuantitativeT2Maps and Synthetic Morphologic Images: A Preliminary Study

Tobias Kober, Tom Hilbert, Yong Zhang, Meng Yang, Jie Liu

Background The application value of T(2)mapping in evaluating cervical cancer (CC) features remains unclear. Purpose To investigate the role of T(2)values in evaluating CC classification, grade, and lymphovascular space invasion (LVSI) in comparison to app ...

WILEY2020